Cancer NetworkOriginal article
<![CDATA[Blood-Based Lung Cancer Screening Tool Earns FDA Breakthrough Device Status]]>
RegulatorySimpleScreen LungPositive
AI Analysis
Summary
SimpleScreen Lung, a blood-based lung cancer detection tool, has earned FDA Breakthrough Device Status. Data supporting the designation were presented at the 2026 AACR Annual Meeting.
Outcome Details
FDA Breakthrough Device Status granted
Importance:7/10
Sentiment:
0.85
FDA Breakthroughblood-based testlung cancerdiagnosticAACR 2026
Read the original article
Published by Cancer Network on August 14, 2026 5:00 PM